VTN and Alzheimer disease: Our research group previously employed quantitative proteomics to characterize the distinct features of Aβ plaques in the brains of AD patients, aged individuals, and APP/PS1 mice, revealing the specific upregulation of synaptic structural proteins and complement proteins within Aβ plaques in AD human brains [13].